(Q43707361)

26 November 2017

High-dose tamoxifen added to concurrent biochemotherapy with decrescendo interleukin-2 in patients with metastatic melanoma (English)

1 reference

26 November 2017

1 reference

1 reference

O'Day SJ

1

1 reference

26 November 2017

Boasberg PD

2

1 reference

26 November 2017

Kristedja TS

3

1 reference

26 November 2017

Martin M

4

1 reference

26 November 2017

Wang HJ

5

1 reference

26 November 2017

Fournier P

6

1 reference

26 November 2017

Cabot M

7

1 reference

26 November 2017

DeGregorio MW

8

1 reference

26 November 2017

Gammon G

9

1 reference

26 November 2017

language of work or name

English

0 references

publication date

1 August 2001

1 reference

26 November 2017

1 reference

26 November 2017

92

1 reference

26 November 2017

3

1 reference

26 November 2017

609-619

1 reference

The incidence of malignant melanoma in the United States: issues as we approach the 21st century

26 November 2017

1 reference

https://api.crossref.org/works/10.1002%2F1097-0142%2820010801%2992%3A3%3C609%3A%3AAID-CNCR1361%3E3.0.CO%3B2-U

Cutaneous melanoma: prognosis and treatment results worldwide

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1097-0142%2820010801%2992%3A3%3C609%3A%3AAID-CNCR1361%3E3.0.CO%3B2-U

Chemotherapy for malignant melanoma: combinations and high doses produce more responses without survival benefit

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1097-0142%2820010801%2992%3A3%3C609%3A%3AAID-CNCR1361%3E3.0.CO%3B2-U

A prospective evaluation of a triple-drug regimen containing cisplatin, vinblastine, and dacarbazine (CVD) for metastatic melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1097-0142%2820010801%2992%3A3%3C609%3A%3AAID-CNCR1361%3E3.0.CO%3B2-U

Sequential chemoimmunotherapy in the treatment of metastatic melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1097-0142%2820010801%2992%3A3%3C609%3A%3AAID-CNCR1361%3E3.0.CO%3B2-U

Treatment of metastatic melanoma with combined chemotherapy containing cisplatin, vinblastine and dacarbazine (CVD) and biotherapy using interleukin-2 and interferon-alpha

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1097-0142%2820010801%2992%3A3%3C609%3A%3AAID-CNCR1361%3E3.0.CO%3B2-U

Multiinstitutional phase II trial of intensive combination chemoimmunotherapy for metastatic melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1097-0142%2820010801%2992%3A3%3C609%3A%3AAID-CNCR1361%3E3.0.CO%3B2-U

Combination of chemotherapy with interleukin-2 and interferon alfa for the treatment of metastatic melanoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1097-0142%2820010801%2992%3A3%3C609%3A%3AAID-CNCR1361%3E3.0.CO%3B2-U

Development of a biochemotherapy regimen with concurrent administration of cisplatin, vinblastine, dacarbazine, interferon alfa, and interleukin-2 for patients with metastatic melanoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1097-0142%2820010801%2992%3A3%3C609%3A%3AAID-CNCR1361%3E3.0.CO%3B2-U

Results of interleukin-2-based treatment in advanced melanoma: a case record-based analysis of 631 patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1097-0142%2820010801%2992%3A3%3C609%3A%3AAID-CNCR1361%3E3.0.CO%3B2-U

Reversal of P-glycoprotein-mediated multidrug resistance by pure anti-oestrogens and novel tamoxifen derivatives

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1097-0142%2820010801%2992%3A3%3C609%3A%3AAID-CNCR1361%3E3.0.CO%3B2-U

Agents that reverse multidrug resistance, tamoxifen, verapamil, and cyclosporin A, block glycosphingolipid metabolism by inhibiting ceramide glycosylation in human cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1097-0142%2820010801%2992%3A3%3C609%3A%3AAID-CNCR1361%3E3.0.CO%3B2-U

Effective combination chemo/hormonal therapy for malignant melanoma: experience with three consecutive trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1097-0142%2820010801%2992%3A3%3C609%3A%3AAID-CNCR1361%3E3.0.CO%3B2-U

The importance of tamoxifen to a cisplatin-containing regimen in the treatment of metastatic melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1097-0142%2820010801%2992%3A3%3C609%3A%3AAID-CNCR1361%3E3.0.CO%3B2-U

Randomized, double-blind, placebo-controlled trial comparing the response rates of carmustine, dacarbazine, and cisplatin with and without tamoxifen in patients with metastatic melanoma. National Cancer Institute of Canada Clinical Trials Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1097-0142%2820010801%2992%3A3%3C609%3A%3AAID-CNCR1361%3E3.0.CO%3B2-U

High-dose tamoxifen as an enhancer of etoposide cytotoxicity. Clinical effects and in vitro assessment in p-glycoprotein expressing cell lines

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1097-0142%2820010801%2992%3A3%3C609%3A%3AAID-CNCR1361%3E3.0.CO%3B2-U

Intermittent high-dose tamoxifen as a potential modifier of multidrug resistance.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1097-0142%2820010801%2992%3A3%3C609%3A%3AAID-CNCR1361%3E3.0.CO%3B2-U

Targeting chemosensitizing doses of toremifene based on protein binding

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1097-0142%2820010801%2992%3A3%3C609%3A%3AAID-CNCR1361%3E3.0.CO%3B2-U

Recent advances in understanding the molecular mechanisms of tamoxifen action

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1097-0142%2820010801%2992%3A3%3C609%3A%3AAID-CNCR1361%3E3.0.CO%3B2-U

Tamoxifen induces selective membrane association of protein kinase C epsilon in MCF-7 human breast cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1097-0142%2820010801%2992%3A3%3C609%3A%3AAID-CNCR1361%3E3.0.CO%3B2-U

A multifactorial analysis of melanoma. IV. Prognostic factors in 200 melanoma patients with distant metastases (stage III)

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1097-0142%2820010801%2992%3A3%3C609%3A%3AAID-CNCR1361%3E3.0.CO%3B2-U

Dimethyl triazeno imidazole carboxamide and combination therapy for melanoma. IV. Late results after complete response to chemotherapy (Central Oncology Group protocols 7130, 7131, and 7131A)

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1097-0142%2820010801%2992%3A3%3C609%3A%3AAID-CNCR1361%3E3.0.CO%3B2-U

Complete responses and long-term survivals after systemic chemotherapy for patients with advanced malignant melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1097-0142%2820010801%2992%3A3%3C609%3A%3AAID-CNCR1361%3E3.0.CO%3B2-U

Sequential chemoimmunotherapy with cisplatin, interleukin-2, and interferon alfa-2a for metastatic melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1097-0142%2820010801%2992%3A3%3C609%3A%3AAID-CNCR1361%3E3.0.CO%3B2-U

A phase II study of dacarbazine and cisplatin in combination with outpatient administered interleukin-2 in metastatic malignant melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1097-0142%2820010801%2992%3A3%3C609%3A%3AAID-CNCR1361%3E3.0.CO%3B2-U

Phase II study of neoadjuvant concurrent biochemotherapy in melanoma patients with local-regional metastases

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1097-0142%2820010801%2992%3A3%3C609%3A%3AAID-CNCR1361%3E3.0.CO%3B2-U

Interferon alfa-2a and interleukin-2 with or without cisplatin in metastatic melanoma: a randomized trial of the European Organization for Research and Treatment of Cancer Melanoma Cooperative Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1097-0142%2820010801%2992%3A3%3C609%3A%3AAID-CNCR1361%3E3.0.CO%3B2-U

Interferon-alpha and interleukin-2 in the treatment of metastatic melanoma. Comparison of two phase II trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1097-0142%2820010801%2992%3A3%3C609%3A%3AAID-CNCR1361%3E3.0.CO%3B2-U

Tamoxifen retards glycosphingolipid metabolism in human cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1097-0142%2820010801%2992%3A3%3C609%3A%3AAID-CNCR1361%3E3.0.CO%3B2-U

Phase III multicenter randomized trial of the Dartmouth regimen versus dacarbazine in patients with metastatic melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1097-0142%2820010801%2992%3A3%3C609%3A%3AAID-CNCR1361%3E3.0.CO%3B2-U

A phase II study of tamoxifen combined with cisplatin-interleukin 2 and alpha-interferon in metastatic melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1097-0142%2820010801%2992%3A3%3C609%3A%3AAID-CNCR1361%3E3.0.CO%3B2-U

Advantages of concurrent biochemotherapy modified by decrescendo interleukin-2, granulocyte colony-stimulating factor, and tamoxifen for patients with metastatic melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1097-0142%2820010801%2992%3A3%3C609%3A%3AAID-CNCR1361%3E3.0.CO%3B2-U

Tamoxifen activates cellular phospholipase C and D and elicits protein kinase C translocation

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1097-0142%2820010801%2992%3A3%3C609%3A%3AAID-CNCR1361%3E3.0.CO%3B2-U

10.1002/1097-0142(20010801)92:3<609::AID-CNCR1361>3.0.CO;2-U

21 January 2018

Identifiers

DOI

1 reference

26 November 2017

1 reference